None listed
Conditions
Brief summary
The study is designed to evaluate the effects of intrajejunal taurocholic acid on the release of glucagon-like peptide 1 (GLP-1) from the small intestine, and the glycaemic response to concomitant intrajejunal glucose infusion in healthy subjects.
Interventions
Each healthy volunteer will undergo two treatments (one with taurocholic acid (TCA) 4g and one with control), in double- blind, randomised fashion, separated by 7 days. On each day a small intestinal catheter will be positioned for TCA or control (saline) infusion into the jejunum during both 30 minutes of fasting (2g TCA or saline control) and 120 minutes of concurrent glucose infusion (2g TCA or saline control, together with 60g glucose).
Sponsors
Royal Adelaide Hospital
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
Male
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Healthy subjects; Body mass index (BMI) 19 - 30 kg/m2; Haemoglobin > 135 g/L
Exclusion criteria
Medications affecting gut function; Alcohol intake >20g daily or cigarette smoking; Significant gastrointestinal disease or surgery; Impaired liver or renal function; Blood donation within 3 months
Outcome results
None listed